Steve DickmanCEO at CBT Advisors
CBT Advisors CEO Steve Dickman has worked in consulting and venture capital for more than twenty years. He founded CBT Advisors in 2003 and has worked on storytelling and strategy with more than three hundred private biotechnology and life sciences clients. Much of the firm’s work focuses on drafting business sections for NASDAQ IPOs. Seventy-seven clients have gone public, raising $9 billion. IPO clients have included Instil Bio, BioAtla, Vor Biopharma, Foghorn Therapeutics, Olema Pharmaceuticals, Legend Biotech, Zentalis Pharmaceuticals, iTeos Therapeutics, Repare Therapeutics, CRISPR Therapeutics, Karuna Therapeutics and others. Previously, Steve was a venture capitalist with TVM Capital, where his investments included Sirna Therapeutics, which was acquired in 2006 by Merck for $1.1 billion, and bluebird bio, which went public on Nasdaq (BLUE) in 2013.